US regulatory status: approved. Molecular target: Integrin alpha-IIb/beta-3.
- Target
- Integrin alpha-IIb/beta-3
- Mechanism
- Integrin alpha-V/beta-3 inhibitor
pharma · Melanoma · Multiple Myeloma · RNA
Atrium Therapeutics
Atrium Therapeutics drug portfolio — 33 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
10578 Science Center Dr, Suite 125, San Diego, California 92121, US HQ
2026 Founded
46 Employees
Public company Type
RNA · NYSE Ticker
Company details
- Status
- Public
- HQ
- 10578 Science Center Dr, Suite 125, San Diego, California 92121, US
- Founded
- 2026
- Employees
- 46
- Programs
- 31
- Drugs
- 33
- Patents
- 37
Atrium Therapeutics pipeline
Portfolio lens on 33 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Atrium Therapeutics drug portfolio — 33 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Aromatase.
- Target
- Aromatase
- Mechanism
- Cytochrome P450 19A1 inhibitor
-
anti-melanoma mab fragments
Various (V09)Various (V09) compound in Atrium Therapeutics's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
Development asset linked to Atrium Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to Atrium Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
US regulatory status: approved.
-
elotuzumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: SLAM family member 7.
- Target
- SLAM family member 7
- Mechanism
- SLAM family member 7 inhibitor
-
US regulatory status: approved. Molecular target: Vitamin D3 receptor.
- Target
- Vitamin D3 receptor
- Mechanism
- Vitamin D receptor agonist
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.
- Target
- Lanosterol 14-alpha demethylase
- Mechanism
- Cytochrome P450 51 inhibitor
-
US regulatory status: approved. Molecular target: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI.
- Target
- Enoyl-[acyl-carrier-protein] reductase [NADH] FabI
- Mechanism
- Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor
-
Development asset linked to Atrium Therapeutics in public FDA and regional records.
-
Development asset linked to Atrium Therapeutics in public FDA and regional records.
-
Development asset linked to Atrium Therapeutics in public FDA and regional records.
-
Development asset linked to Atrium Therapeutics in public FDA and regional records.
-
Development asset linked to Atrium Therapeutics in public FDA and regional records. Mechanism: Mitochondrial complex I (NADH dehydrogenase) inhibitor.
- Mechanism
- Mitochondrial complex I (NADH dehydrogenase) inhibitor
-
metformin hydrochloride
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Mitochondrial complex I (NADH dehydrogenase).
- Target
- Mitochondrial complex I (NADH dehydrogenase)
- Mechanism
- Mitochondrial complex I (NADH dehydrogenase) inhibitor
-
nivolumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
US regulatory status: approved. Molecular target: Isocitrate dehydrogenase [NADP] cytoplasmic.
- Target
- Isocitrate dehydrogenase [NADP] cytoplasmic
- Mechanism
- Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor
-
Development asset linked to Atrium Therapeutics in public FDA and regional records. Mechanism: Adrenergic receptor alpha antagonist.
- Mechanism
- Adrenergic receptor alpha antagonist
-
US regulatory status: approved. Molecular target: Adrenergic receptor alpha.
- Target
- Adrenergic receptor alpha
- Mechanism
- Adrenergic receptor alpha antagonist
-
Development asset linked to Atrium Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Cholinesterases; ACHE & BCHE.
- Target
- Cholinesterases; ACHE & BCHE
- Mechanism
- Cholinesterases; ACHE & BCHE inhibitor
-
Development asset linked to Atrium Therapeutics in public FDA and regional records. Mechanism: Sodium channel alpha subunit blocker.
- Mechanism
- Sodium channel alpha subunit blocker
-
rufinamide
Nervous system (N03)US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
- Target
- Sodium channel alpha subunit
- Mechanism
- Sodium channel alpha subunit blocker
-
Development asset linked to Atrium Therapeutics in public FDA and regional records.
-
Development asset linked to Atrium Therapeutics in public FDA and regional records.
-
Development asset linked to Atrium Therapeutics in public FDA and regional records.
-
Development asset linked to Atrium Therapeutics in public FDA and regional records.
-
Development asset linked to Atrium Therapeutics in public FDA and regional records.
-
Development asset linked to Atrium Therapeutics in public FDA and regional records.